而对于不明原因的VTE,抗凝治疗3个月后需重新评估患者的风险收益比(risk-benefit ratio),以决定是否继续抗凝。其中出血风险小,抗凝监测负担轻的患者,建议可采用更长时间的抗凝。
基于8个网页-相关网页
Countermeasures: fair use, temperance drug use, develop the risk-benefit ratio, low residue and selective pesticides.
对策:公道用药,节制用药,研制高效低毒,低残留并有选择性的农药。
Peters et al suggest that the procedure should be reserved only for research protocols with rigorous analysis of the risk-benefit ratio.
Peters等人建议,此手术应限制在研究框架内,需严格分析其风险-效益比。
There are too many known risks associated with this class of medications, and we would need a lot more research to figure out the risk-benefit ratio.
“有太多的已知风险与此类药物相关,我们将需要进一步的研究,以指出的风险-效益比”。
应用推荐